142 related articles for article (PubMed ID: 37272088)
21. FOXM1 confers acquired cisplatin resistance in breast cancer cells.
Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW
Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070
[TBL] [Abstract][Full Text] [Related]
22. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
23. Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines.
Choi HS; Kim YK; Hwang KG; Yun PY
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255409
[TBL] [Abstract][Full Text] [Related]
24. Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer.
Miao Y; Konno Y; Wang B; Zhu L; Zhai T; Ihira K; Kobayashi N; Watari H; Jin X; Yue J; Dong P; Fang M
J Transl Med; 2023 Feb; 21(1):151. PubMed ID: 36829176
[TBL] [Abstract][Full Text] [Related]
25. [Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells].
Gong XD; Yuan HH; Wang JY; Guo YH; Shi J; Jiang B
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):572-8. PubMed ID: 24314213
[TBL] [Abstract][Full Text] [Related]
26. [Bcl-2 associated athanogene 3 affects the epithelial-mesenchymal transition in human cervical cancer].
Wei L; Qin XP; Zhao XX; Wang W
Zhonghua Fu Chan Ke Za Zhi; 2017 Aug; 52(8):551-557. PubMed ID: 28851173
[No Abstract] [Full Text] [Related]
27. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Liang XD; Dai YC; Li ZY; Gan MF; Zhang SR; Yin-Pan ; Lu HS; Cao XQ; Zheng BJ; Bao LF; Wang DD; Zhang LM; Ma SL
PLoS One; 2014; 9(6):e97739. PubMed ID: 24905462
[TBL] [Abstract][Full Text] [Related]
28. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.
Karunarathna U; Kongsema M; Zona S; Gong C; Cabrera E; Gomes AR; Man EP; Khongkow P; Tsang JW; Khoo US; Medema RH; Freire R; Lam EW
Oncogene; 2016 Mar; 35(11):1433-44. PubMed ID: 26148240
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.
Jiang L; Wang P; Chen L; Chen H
Int J Clin Exp Pathol; 2014; 7(9):5450-60. PubMed ID: 25337187
[TBL] [Abstract][Full Text] [Related]
30. [EBF1 Promotes the Sensitivity of Cervical Cancer Cells to Cisplatin via Activating FBN1 Transcription].
Shen NN; Lin JH; Liu PP
Mol Biol (Mosk); 2023; 57(3):503-504. PubMed ID: 37326054
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.
Huang X; Qin J; Lu S
Int J Clin Exp Pathol; 2015; 8(2):1515-24. PubMed ID: 25973036
[TBL] [Abstract][Full Text] [Related]
32. FoxM1 mediates resistance to herceptin and paclitaxel.
Carr JR; Park HJ; Wang Z; Kiefer MM; Raychaudhuri P
Cancer Res; 2010 Jun; 70(12):5054-63. PubMed ID: 20530690
[TBL] [Abstract][Full Text] [Related]
33. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
34. PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway.
Duan W; Liu X
Ann Clin Lab Sci; 2020 Jul; 50(4):512-518. PubMed ID: 32826249
[TBL] [Abstract][Full Text] [Related]
35. CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.
Liu J; Wang M; Zhang X; Wang Q; Qi M; Hu J; Zhou Z; Zhang C; Zhang W; Zhao W; Wang X
Tumour Biol; 2016 Feb; 37(2):2673-82. PubMed ID: 26404133
[TBL] [Abstract][Full Text] [Related]
36. Aberrantly Expressed Timeless Regulates Cell Proliferation and Cisplatin Efficacy in Cervical Cancer.
Zhou J; Zhang Y; Zou X; Kuai L; Wang L; Wang J; Shen F; Hu J; Zhang X; Huang Y; Chen Y
Hum Gene Ther; 2020 Mar; 31(5-6):385-395. PubMed ID: 31870179
[TBL] [Abstract][Full Text] [Related]
37. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
38. Enhancer of mRNA Decapping protein 4 (EDC4) interacts with replication protein a (RPA) and contributes to Cisplatin resistance in cervical Cancer by alleviating DNA damage.
Wu X; Zhong Y; Chen Q; Zhang X; Zhang H
Hereditas; 2020 Oct; 157(1):41. PubMed ID: 33054858
[TBL] [Abstract][Full Text] [Related]
39. FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression.
Petrovic V; Costa RH; Lau LF; Raychaudhuri P; Tyner AL
J Biol Chem; 2008 Jan; 283(1):453-460. PubMed ID: 17984092
[TBL] [Abstract][Full Text] [Related]
40. Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Jun; 27(5):887-894. PubMed ID: 28498253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]